Information about Altretamine
Altretamine is an orally administered alkylating agent, formerly known as hexamethylmelamine, which is currently used as a secondary therapy for advanced ovarian carcinoma.
Liver safety of Altretamine
Altretamine therapy has been associated with low rates of serum enzyme elevations during therapy and with rare instances of acute, clinically apparent injury.
Mechanism of action of Altretamine
Altretamine (al tret' a meen) is a synthetic, orally available alkylating agent belonging to the methylmelamine class of these agents. The alkylating agents act by causing modification and cross linking of DNA, thus inhibiting DNA, RNA and protein synthesis and causing cell death in rapidly dividing cells.
FDA approval information for Altretamine
Altretamine was approved for use in the United States in 1990. Current indications are advanced ovarian carcinoma in patients who have failed primary therapy with platinum-containing or other alkylating agents.
Brand name for Altretamine
Altretamine is available in capsules of 50 mg under the brand name Hexalen.
Dosage and administration for Altretamine
The recommended dose varies by indication and body surface area and it is typically given orally for 14 to 21 days in 28 day cycles.
Side effects of Altretamine
Learn more about Altretamine
Latest research (Pubmed)